• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

老年头颈部鳞状细胞癌患者采用现代放疗技术的术后放化疗:临床实践中权衡治疗方式利弊的挑战

Postoperative Radiochemotherapy Using Modern Radiotherapy Techniques in Elderly Patients with Head and Neck Squamous Cell Carcinoma: The Challenge of Weighing Up Benefits and Harms of Treatment Modalities in Clinical Practice.

作者信息

Leu Martin, Patzer Christoph, Guhlich Manuel, Possiel Jacqueline, Pilavakis Yiannis, Schirmer Markus Anton, Rieken Stefan, Dröge Leif Hendrik

机构信息

Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany.

Department of Otorhinolaryngology, University Medical Center Göttingen, 37075 Göttingen, Germany.

出版信息

Cancers (Basel). 2021 Jul 6;13(14):3384. doi: 10.3390/cancers13143384.

DOI:10.3390/cancers13143384
PMID:34298599
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8307771/
Abstract

Locally advanced head and neck squamous cell carcinomas (HNSCC) are often managed with surgery followed by postoperative radiochemotherapy (RCT). With the general increase in life expectancy, the proportion of elderly patients with HNSCC is expected to grow rapidly. Until now, a deeper understanding of specific management strategies for these patients in clinical routine was lacking. In the present study, we compared elderly patients (≥70 years, = 52) and younger patients ( = 245) treated with postoperative RCT for HNSCC at our tertiary cancer center. All patients were irradiated with modern radiotherapy techniques (IMRT/VMAT). Patients ≥70 years of age had more comorbidities. Additionally, elderly patients less frequently received concomitant systemic treatment. The rates of mucositis and dermatitis were lower in patients ≥70 years. Elderly patients had significantly worse overall and progression-free survival. Locoregional and distant control were comparable in elderly and younger patients. In conclusion, postoperative RCT is a safe and effective treatment option in patients ≥70 years. In light of comorbidities and poor overall survival rates, benefits and harms of radiotherapy and concomitant systemic treatment should be weighed carefully. When exclusively applying up-to-date radiotherapy techniques with, at the same time, careful use of concomitant systemic therapy, favorable acute toxicity profiles are achieved.

摘要

局部晚期头颈部鳞状细胞癌(HNSCC)通常采用手术治疗,术后进行放化疗(RCT)。随着预期寿命的普遍提高,老年HNSCC患者的比例预计将迅速增长。到目前为止,临床常规中对这些患者的具体管理策略缺乏更深入的了解。在本研究中,我们比较了在我们的三级癌症中心接受HNSCC术后RCT治疗的老年患者(≥70岁,n = 52)和年轻患者(n = 245)。所有患者均采用现代放疗技术(IMRT/VMAT)进行照射。≥70岁的患者合并症更多。此外,老年患者接受同步全身治疗的频率较低。≥70岁患者的黏膜炎和皮炎发生率较低。老年患者的总生存期和无进展生存期明显较差。老年患者和年轻患者的局部区域控制和远处控制相当。总之,术后RCT是≥70岁患者的一种安全有效的治疗选择。鉴于合并症和总体生存率较低,应仔细权衡放疗和同步全身治疗的利弊。当专门应用最新的放疗技术,同时谨慎使用同步全身治疗时,可获得良好的急性毒性反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a08/8307771/3a81a4d8ac15/cancers-13-03384-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a08/8307771/a2e78061bd10/cancers-13-03384-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a08/8307771/ce29c925d037/cancers-13-03384-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a08/8307771/67c78eea2358/cancers-13-03384-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a08/8307771/3269cc06342b/cancers-13-03384-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a08/8307771/3a81a4d8ac15/cancers-13-03384-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a08/8307771/a2e78061bd10/cancers-13-03384-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a08/8307771/ce29c925d037/cancers-13-03384-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a08/8307771/67c78eea2358/cancers-13-03384-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a08/8307771/3269cc06342b/cancers-13-03384-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a08/8307771/3a81a4d8ac15/cancers-13-03384-g005.jpg

相似文献

1
Postoperative Radiochemotherapy Using Modern Radiotherapy Techniques in Elderly Patients with Head and Neck Squamous Cell Carcinoma: The Challenge of Weighing Up Benefits and Harms of Treatment Modalities in Clinical Practice.老年头颈部鳞状细胞癌患者采用现代放疗技术的术后放化疗:临床实践中权衡治疗方式利弊的挑战
Cancers (Basel). 2021 Jul 6;13(14):3384. doi: 10.3390/cancers13143384.
2
[SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].同步放化疗联合顺铂治疗局部晚期头颈部鳞状细胞癌(SCHNC)。早期结果及毒性评估
Otolaryngol Pol. 2011 Sep;65(5 Suppl):117-25. doi: 10.1016/S0030-6657(11)70719-3.
3
Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?老年头颈部癌症患者的放射治疗:标准治疗在老年人中的价值如何?
Radiat Oncol. 2020 Feb 4;15(1):31. doi: 10.1186/s13014-020-1481-z.
4
Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer.氨磷汀在晚期头颈癌同步放化疗中的应用
Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):4-13. doi: 10.1053/srao.2002.31356.
5
Clinical outcome and toxicity after simultaneous integrated boost IMRT in head and neck squamous cell cancer patients.头颈部鳞状细胞癌患者同时整合增敏调强放疗后的临床结果和毒性。
Oral Oncol. 2019 Nov;98:132-140. doi: 10.1016/j.oraloncology.2019.09.012. Epub 2019 Oct 3.
6
Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate.头颈部复发性和第二原发性鳞状细胞癌:何时以及如何再次放疗。
Head Neck. 2015 Jan;37(1):134-50. doi: 10.1002/hed.23542. Epub 2014 Jan 31.
7
IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80.头颈部恶性肿瘤的调强放疗/容积调强弧形放疗:80岁患者的治疗结果
Strahlenther Onkol. 2016 Aug;192(8):526-36. doi: 10.1007/s00066-016-0986-8. Epub 2016 Jun 15.
8
Outcomes of postoperative simultaneous modulated accelerated radiotherapy for head-and-neck squamous cell carcinoma.头颈部鳞状细胞癌术后同步调强加速放疗的结果。
Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):140-9. doi: 10.1016/j.ijrobp.2010.04.068. Epub 2010 Aug 21.
9
Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".头颈部鳞状细胞癌患者的术后(化疗)放疗——来自临床合作组“头颈部癌症个体化放疗”队列的临床结果。
Radiat Oncol. 2018 Jul 3;13(1):123. doi: 10.1186/s13014-018-1067-1.
10
Evidence-based radiation oncology in head and neck squamous cell carcinoma.头颈部鳞状细胞癌的循证放射肿瘤学
Radiother Oncol. 2007 Oct;85(1):156-70. doi: 10.1016/j.radonc.2007.04.002. Epub 2007 May 4.

引用本文的文献

1
Treatment of non-small cell lung cancer: advances following the introduction of PET-CT and IMRT/VMAT.非小细胞肺癌的治疗:PET-CT和IMRT/VMAT引入后的进展
Strahlenther Onkol. 2025 Mar 6. doi: 10.1007/s00066-025-02377-0.
2
Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review).扩大联合免疫化疗和免疫放疗在头颈部癌治疗中的作用(综述)
Oncol Lett. 2023 Jul 17;26(3):372. doi: 10.3892/ol.2023.13958. eCollection 2023 Sep.
3
Impact of upgraded radiotherapy system on outcomes in postoperative head and neck squamous cell carcinoma patients.

本文引用的文献

1
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.西妥昔单抗、多西他赛和顺铂与顺铂、氟尿嘧啶和西妥昔单抗联合用于复发性或转移性头颈部鳞状细胞癌患者的一线治疗(GORTEC 2014-01 TPExtreme):一项多中心、开放标签、随机、2 期临床试验。
Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5.
2
Head and neck squamous cell carcinoma.头颈部鳞状细胞癌
Nat Rev Dis Primers. 2020 Nov 26;6(1):92. doi: 10.1038/s41572-020-00224-3.
3
升级后的放射治疗系统对术后头颈部鳞状细胞癌患者治疗结果的影响。
Rep Pract Oncol Radiother. 2022 Dec 29;27(6):954-962. doi: 10.5603/RPOR.a2022.0120. eCollection 2022.
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
口腔、喉、口咽和下咽鳞状细胞癌:EHNS-ESMO-ESTRO诊断、治疗及随访临床实践指南
Ann Oncol. 2020 Nov;31(11):1462-1475. doi: 10.1016/j.annonc.2020.07.011. Epub 2020 Oct 23.
4
Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma.头颈部鳞状细胞癌患者根治性同期放化疗中个体化/动态顺铂方案的 II 期临床试验。
Cancer Med. 2020 Dec;9(24):9256-9265. doi: 10.1002/cam4.3529. Epub 2020 Oct 19.
5
Head and neck squamous cell carcinoma in young patients: a 26-year clinicopathologic retrospective study in a Brazilian specialized center.年轻患者头颈部鳞状细胞癌:巴西一家专门中心的 26 年临床病理回顾性研究。
Med Oral Patol Oral Cir Bucal. 2020 May 1;25(3):e416-e424. doi: 10.4317/medoral.23461.
6
Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?老年头颈部癌症患者的放射治疗:标准治疗在老年人中的价值如何?
Radiat Oncol. 2020 Feb 4;15(1):31. doi: 10.1186/s13014-020-1481-z.
7
Outcomes for Elderly Patients Aged 70 to 80 Years or Older with Locally Advanced Oral Cavity Squamous Cell Carcinoma: A Propensity Score-Matched, Nationwide, Oldest Old Patient-Based Cohort Study.70至80岁及以上局部晚期口腔鳞状细胞癌老年患者的治疗结果:一项倾向评分匹配的、全国性的、基于高龄老人的队列研究。
Cancers (Basel). 2020 Jan 21;12(2):258. doi: 10.3390/cancers12020258.
8
Eliminating Postoperative Radiation to the Pathologically Node-Negative Neck: Long-Term Results of a Prospective Phase II Study.消除病理淋巴结阴性颈部的术后放疗:一项前瞻性 II 期研究的长期结果。
J Clin Oncol. 2019 Oct 1;37(28):2548-2555. doi: 10.1200/JCO.19.00186. Epub 2019 Jun 27.
9
Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer.低剂量与高剂量顺铂:头颈部癌59项放化疗试验的经验教训
Front Oncol. 2019 Feb 21;9:86. doi: 10.3389/fonc.2019.00086. eCollection 2019.
10
Chemoradiotherapy as Definitive Treatment for Elderly Patients with Head and Neck Cancer.化放疗作为老年头颈部癌症患者的确定性治疗方法。
Biomed Res Int. 2018 Jan 17;2018:3508795. doi: 10.1155/2018/3508795. eCollection 2018.